Must Canada Become The Drugstore To The World?
This paper examines developments affecting the controversial and important issue of gray market importation of patented and branded pharmaceutical products, particularly developments in Europe, Canada and the United States. Issues considered include the doctrine of exhaustion of intellectual property, which has implications for the ability of intellectual property rights holders to prevent importation of goods first sold abroad (gray market goods). The ability of rights holders to prevent such imports in turn has implications for international trade. Presented at the 15th International Conference, Istanbul, Turkey, May 2005.
To our knowledge, this item is not available for
download. To find whether it is available, there are three
1. Check below under "Related research" whether another version of this item is available online.
2. Check on the provider's web page whether it is in fact available.
3. Perform a search for a similarly titled item that would be available.
|Date of creation:||18 May 2005|
|Date of revision:|
|Contact details of provider:|| |
More information through EDIRC
When requesting a correction, please mention this item's handle: RePEc:bep:itfapp:1038. See general information about how to correct material in RePEc.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: (Christopher F. Baum)
If references are entirely missing, you can add them using this form.